电子邮件 | isa***@***.com | 获取Email |
---|
电子邮件 | isa***@***.com | 获取Email |
---|
OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company's most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.
公司 | OSE Immunotherapeutics |
---|---|
职位 | Bioinformaticienne |
地点 | France |
http://www.linkedin.com/in/isabelle-girault-757a2430 | |
部门 | |
头衔 | Bio(Immuno)informaticienne chez OSE Immunotherapeutics |
OSE Immunotherapeutics Bioinformaticienne
2020-01-01 -
Gustave Roussy Ingénieure de Recherche
2012-02-01 - 2020-01-01
INSERM Ingénieure de Recherche - Coordinatrice d'études biologiques
2004-09-01 - 2012-01-01
INSERM Ingénieure
2002-09-01 - 2004-09-01
Isabelle Girault 在 OSE Immunotherapeutics 担任 Bio(Immuno)informaticienne chez OSE Immunotherapeutics
Isabelle Girault 在 OSE Immunotherapeutics 的职位是 Bio(Immuno)informaticienne chez OSE Immunotherapeutics
Isabelle Girault 的电子邮件地址是 isa***@***.com
Isabelle Girault 的电话号码是 -
Isabelle Girault 的公司电话号码是 +332****
Isabelle Girault 在 research 工作。
Isabelle Girault 的一些同事包括Laurie Cordonnier、Isabelle Girault、Emmanuelle Wilhelm、Julien MaletVirginie Donne、。
Isabelle Girault联系方式: 电子邮件地址:isa***@***.com 电话号码:-
Isabelle Girault 的个人领英是:http://www.linkedin.com/in/isabelle-girault-757a2430
Isabelle Girault 的办公地点:22 boulevard benoni goullin, nantes, pays de la loire, france
Top-ranked on G2 Crowd
全球B2B企业库 海关贸易数据 展会采购数据
全球B2B企业库
海关贸易数据
展销采购数据
Top-ranked on G2 Crowd